Robert Booth PhD
Founder and Chief Executive Officer
Robert Booth PhD
Chief Executive Officer, Virobay
Robert F. Booth, Ph.D. has served as our Chief Executive Officer, President, Secretary and a member of our board of directors since May 2010 and he was previously our Executive Chairman and a member of our board of directors from July 2006 to May 2010. From July 2006 to May 2010, Dr. Booth served as an Operating Partner and Senior Advisor at TPG Biotechnology Partners, LP, a venture capital company. From December 2006 to July 2007, Dr. Booth served as the acting Chief Scientific Officer of Galleon Pharmaceuticals, Inc., a company which is developing new therapeutics for diseases of the respiratory system. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics Corporation, or Celera, a drug discovery and development company. Dr. Booth served as Senior Vice President at Roche Bioscience, a part of F. Hoffmann-La Roche Ltd, or Roche, from 1996 to 2002, where he was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. From 1989 to December 1995, Dr. Booth served as Director of Biology for Roche Products Ltd, a part of Roche’s research operation, which was located in the United Kingdom. Dr. Booth currently serves on the boards of directors of Pharmacyclics, Inc., Galleon Pharmaceuticals, Inc. and Glialogix, Inc., and is Chairman of the Scientific Advisory Board at Galleon Pharmaceuticals, Inc. Dr. Booth also serves as a member of the Scientific Advisory Boards of ShangPharma Corporation, Elcelyx Therapeutics, Inc. and NaZura Biohealth, Inc. Dr. Booth received a B.Sc. and a Ph.D. from the University of London in biochemistry.